CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.94
+0.10 (+1.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.84
Open5.81
Bid0.00 x 800
Ask0.00 x 800
Day's Range5.76 - 5.96
52 Week Range1.20 - 7.19
Volume114,508
Avg. Volume143,882
Market Cap182.841M
Beta (3Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-1.28
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.25
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has closed its previously announced underwritten public offering of 7,263,158 shares of its common stock at a price to the public of $4.75 per share for gross proceeds of approximately $34.5 million. Chiasma anticipates using the proceeds from the offering primarily for development costs, including the conduct of its ongoing Phase 3 clinical trials of octreotide capsules, preparation for potential commercialization in the United States, and for working capital and other general corporate purposes. H.C. Wainwright & Co., Roth Capital Partners, Brookline Capital Markets, a division of CIM Securities, LLC and LifeSci Capital LLC acted as co-managers for the offering.

  • GlobeNewswire24 days ago

    Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of an underwritten public offering of 6,315,790 shares of its common stock at a price to the public of $4.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Chiasma. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to an additional 947,368 shares of its common stock at the public offering price, less underwriting discounts and commissions.

  • Benzinga24 days ago

    5 Stocks Moving In Thursday's After-Hours Session

    Gainers: Science Applications International Corp (NYSE: SAIC ) shares are up 7 percent after reporting a fourth-quarter earnings beat. Adjusted earnings came in at $1.17, beating estimates by 38 cents. ...

  • GlobeNewswire24 days ago

    Chiasma Announces Proposed Offering of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has commenced an underwritten public offering of its common stock. In addition, Chiasma expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswirelast month

    Chiasma Announces Three Poster Presentations at ENDO 2019

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced three poster presentations at ENDO 2019: The Endocrine Society’s Annual Meeting and Expo, which is being held March 23-26 in New Orleans. William Ludlam, MD, PhD, Senior Vice President of Clinical Development and Medical Affairs, said, “We are pleased to present three posters at ENDO this year to further educate the endocrinology community on the ongoing challenges associated with the maintenance treatment of adults suffering from acromegaly. Mark Fitzpatrick, Chief Executive Officer of Chiasma, commented, “Our octreotide capsules product candidate, which we have conditionally trade named MYCAPSSA®, is currently being evaluated in two Phase 3 clinical trials and, if approved, could represent a new treatment paradigm by being the first orally-administered somatostatin analog.

  • GlobeNewswirelast month

    Chiasma Reports Fourth Quarter and Year End 2018 Results

    On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019 Assuming positive OPTIMAL data,.

  • GlobeNewswire2 months ago

    Chiasma to Participate in Three Investor Conferences in March

    WALTHAM, Mass., March 04, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • GlobeNewswire2 months ago

    Chiasma Announces Support for Rare Disease Day 2019

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced its support for the patient and research communities in recognition of Rare Disease Day 2019. “The theme of Rare Disease Day 2019, ‘Bridging health and social care,’ strikes at the heart of what we are working towards here at Chiasma to improve the lives of people afflicted with acromegaly,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?
    Simply Wall St.2 months ago

    Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...

  • GlobeNewswire4 months ago

    Chiasma Previews Important Upcoming Milestones

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today previewed anticipated upcoming corporate milestones and commented on the significant progress made by the company in 2018. “During 2018, we completed the required enrollment in both of our Phase 3 clinical trials of our investigational octreotide capsules product candidate, which we have conditionally trade-named Mycapssa®, and with those trials progressing as planned, we believe we have set the stage for a catalyst-rich 2019 including the announcement of topline data evaluating Mycapssa’s efficacy as potentially the first oral somatostatin analog for the maintenance therapy of adult acromegaly patients,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • Do Directors Own Chiasma, Inc. (NASDAQ:CHMA) Shares?
    Simply Wall St.4 months ago

    Do Directors Own Chiasma, Inc. (NASDAQ:CHMA) Shares?

    Every investor in Chiasma, Inc. (NASDAQ:CHMA) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease Read More...

  • GlobeNewswire5 months ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Associated Press5 months ago

    Chiasma: 3Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. In the final minutes of trading on Thursday, the company's shares hit $4.20. A year ago, they were trading ...

  • GlobeNewswire5 months ago

    Chiasma Reports Third Quarter 2018 Results

    Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient.

  • GlobeNewswire6 months ago

    Chiasma Supports Acromegaly Awareness Day

    Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. “Today, we acknowledge the acromegaly patients, their families and advocates, as well as the clinical thought leaders who have been instrumental in our efforts to develop an oral treatment alternative for this rare but serious disease,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • Benzinga7 months ago

    The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA)
    Simply Wall St.7 months ago

    One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA)

    If you’re interested in Chiasma Inc (NASDAQ:CHMA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impactRead More...

  • Associated Press8 months ago

    Chiasma: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 36 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.25. A year ago, they were trading at $1.45. _____ ...